126 related articles for article (PubMed ID: 34210490)
1. Genetic Contribution to Metastatic Prostate Cancer.
Sokolova AO; Obeid EI; Cheng HH
Urol Clin North Am; 2021 Aug; 48(3):349-363. PubMed ID: 34210490
[TBL] [Abstract][Full Text] [Related]
2. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
Siebert AL; Szymaniak BM; Numan Y; Morgans AK
Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
[TBL] [Abstract][Full Text] [Related]
3. Germline contributions to metastatic prostate cancer.
Cheng HH
Can J Urol; 2019 Oct; 26(5 Suppl 2):19-21. PubMed ID: 31629420
[TBL] [Abstract][Full Text] [Related]
4. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Lozano R; Castro E; Aragón IM; Cendón Y; Cattrini C; López-Casas PP; Olmos D
Br J Cancer; 2021 Feb; 124(3):552-563. PubMed ID: 33106584
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
6. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O
Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945
[TBL] [Abstract][Full Text] [Related]
7. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Pritchard CC; Mateo J; Walsh MF; De Sarkar N; Abida W; Beltran H; Garofalo A; Gulati R; Carreira S; Eeles R; Elemento O; Rubin MA; Robinson D; Lonigro R; Hussain M; Chinnaiyan A; Vinson J; Filipenko J; Garraway L; Taplin ME; AlDubayan S; Han GC; Beightol M; Morrissey C; Nghiem B; Cheng HH; Montgomery B; Walsh T; Casadei S; Berger M; Zhang L; Zehir A; Vijai J; Scher HI; Sawyers C; Schultz N; Kantoff PW; Solit D; Robson M; Van Allen EM; Offit K; de Bono J; Nelson PS
N Engl J Med; 2016 Aug; 375(5):443-53. PubMed ID: 27433846
[TBL] [Abstract][Full Text] [Related]
8. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
9. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
10. Germline genetics of prostate cancer.
Khan HM; Cheng HH
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S3-S12. PubMed ID: 35657157
[TBL] [Abstract][Full Text] [Related]
11. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
[TBL] [Abstract][Full Text] [Related]
12. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O
JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552
[TBL] [Abstract][Full Text] [Related]
14. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract][Full Text] [Related]
15. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
16. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
[TBL] [Abstract][Full Text] [Related]
17. Germline BLM mutations and metastatic prostate cancer.
Ledet EM; Antonarakis ES; Isaacs WB; Lotan TL; Pritchard C; Sartor AO
Prostate; 2020 Feb; 80(2):235-237. PubMed ID: 31816118
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
Nientiedt C; Endris V; Jenzer M; Mansour J; Sedehi NTP; Pecqueux C; Volckmar AL; Leichsenring J; Neumann O; Kirchner M; Hoveida S; Lantwin P; Kaltenecker K; Dieffenbacher S; Gasch C; Hofer L; Franke D; Tosev G; Görtz M; Schütz V; Radtke JP; Nyarangi-Dix J; Hatiboglu G; Simpfendörfer T; Schönberg G; Isaac S; Teber D; Koerber SA; Christofi G; Czink E; Kreuter R; Apostolidis L; Kratochwil C; Giesel F; Haberkorn U; Debus J; Sültmann H; Zschäbitz S; Jäger D; Duensing A; Schirmacher P; Grüllich C; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2020 Jul; 38(7):637.e17-637.e27. PubMed ID: 32280037
[TBL] [Abstract][Full Text] [Related]
19. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
Connors LM
Clin J Oncol Nurs; 2019 Feb; 23(1):32-35. PubMed ID: 30681994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
